Tiziana Life Sciences (TILS) Interim Results for the Six Months Ended 30 June 2019

Advancing pipeline of next generation therapeutics and diagnostics for oncology and immune diseases of high unmet need London, 30 September 2019 – Tiziana Life Sciences plc (“Tiziana”, AIM: TILS, NASDAQ: TLSA), the research and clinical stage biotechnology company focussing on proprietary drug candidates to treat cancer and autoimmune diseases, today announces its interim results for […]